黄曲霉毒素 D1 | 52373-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 黄曲霉毒素 D1
• 中文别名: 黄曲霉毒素D1
• 英文名称: Aflatoxin D1
• 英文别名: 3-[(3aR,8bS)-8-hydroxy-6-methoxy-3a,8b-dihydrofuro[2,3-b][1]benzofuran-7-yl]cyclopent-2-en-1-one
• CAS: 52373-83-8
• 化学式: C₁₆H₁₄O₅
• 分子量: 286.28
• InChiKey: JRUMBKYTDKXCJC-MGPLVRAMSA-N

物化性质

• 沸点：
  389.8±42.0 °C(Predicted)
• 密度：
  1.418±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Methods and compositions for detecting fungi and mycotoxins
  申请人：AdvaTect Diagnostics, LLC

  公开号：US10036748B2

  公开（公告）日：2018-07-31

  The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.

  本发明涉及一种鉴定患者组织或体液中特定真菌种类的方法。该方法包括以下步骤：从患者组织或体液中提取和回收真菌物种的 DNA，扩增 DNA，将探针与 DNA 杂交以特异性鉴定真菌物种，以及特异性鉴定真菌物种。本发明还涉及一种鉴定患者组织或体液中霉菌毒素的方法。该方法包括以下步骤：从患者组织或体液中提取和回收霉菌毒素，将霉菌毒素与针对霉菌毒素的抗体接触，以及鉴定霉菌毒素。这两种方法都可用于确定患者是否有可能或已经出现与真菌感染有关的疾病状态，并为患者制定有效的治疗方案。
• Methods and Compositions for Identifying Mycotoxins and Fungal Species
  申请人：Hooper Dennis G.

  公开号：US20100075322A1

  公开（公告）日：2010-03-25

  The invention relates to a method of testing for a mycotoxin in patient tissue or body fluid and testing for a fungal species in the patient tissue or body fluid. The method can also be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.
• Methods And Compositions For Detecting Fungi And Mycotoxins
  申请人：Medical Service Consultation International, LLC

  公开号：US20130059307A1

  公开（公告）日：2013-03-07

  The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.
• US20140342927A1
  申请人：——

  公开号：US20140342927A1

  公开（公告）日：2014-11-20
• METHOD AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINS
  申请人：Medical Service Consultation International LLC

  公开号：US20150337396A1

  公开（公告）日：2015-11-26

  The invention relates to a method of identifying a specific fungal species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the fungal species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the fungal species, and specifically identifying the fungal species. The invention also relates to a method of identifying a mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the mycotoxin from the patient tissue or body fluid, contacting the mycotoxin with an antibody directed against the mycotoxin, and identifying the myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient.